Bristol Myers cuts mid-stage NASH, anti-TIGIT programs

Bris­tol My­ers Squibb dis­closed Thurs­day at its R&D Day that it cut six pro­grams, in­clud­ing mid-stage drug can­di­dates for NASH and sol­id tu­mors.

The New Jer­sey phar­ma com­pa­ny axed an siR­NA for NASH, known as HSP47, which it li­censed from Nit­to Denko for $100 mil­lion up­front in 2016. Bris­tol My­ers com­plet­ed a Phase II study in 2019 in­ves­ti­gat­ing the ther­a­py in pa­tients with ad­vanced liv­er fi­bro­sis, or scar tis­sue buildup, af­ter they were cured of he­pati­tis C. It had test­ed two dif­fer­ent dos­es ver­sus place­bo in 61 pa­tients, but both dos­es failed to make a dif­fer­ence in liv­er scar­ring com­pared to place­bo, ac­cord­ing to re­sults in the fed­er­al clin­i­cal tri­als data­base.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.